Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women, respectively, thus representing the 7th most common cancer in men and the 10th most common cancer in women [1] . However, available statistics include not only renal parenchymal tumours, but also urothelial cancer of the renal pelvis; renal cell carcinoma (RCC) accounts for ∼80% of all kidney cancers.
incidence and epidemiology
Kidney cancer accounts for 5% and 3% of all adult malignancies in men and women, respectively, thus representing the 7th most common cancer in men and the 10th most common cancer in women [1] . However, available statistics include not only renal parenchymal tumours, but also urothelial cancer of the renal pelvis; renal cell carcinoma (RCC) accounts for ∼80% of all kidney cancers.
After over two decades of increasing rates, RCC incidence trends worldwide have shown signs of plateauing or decreasing in recent years. Furthermore, kidney cancer mortality rates overall have levelled. These patterns are consistent with reports of incidental diagnosis and downward shift of tumour stage and size; indeed, the widespread use of non-invasive radiological techniques [e.g. ultrasonography (US), computed tomography (CT)] allows the frequent detection of early and small RCCs, which are potentially curable.
Beyond well-known risk factors for RCC, such as cigarette smoking, obesity and hypertension, evidence is accumulating to suggest an aetiological or, on the contrary, a protective role, for additional factors [2] , such as trichloroethylene. Furthermore, RCC also appears to be more common in patients with endstage renal failure or acquired renal cystic disease, and in patients on dialysis, those who have had kidney transplantation, or those with tuberous sclerosis syndrome.
Approximately 2%-3% of all RCCs are hereditary and several autosomal dominant syndromes are described, each with a distinct genetic basis and phenotype, the most common one being Von Hippel Lindau (VHL) disease.
diagnosis
As stated above, >50% of RCCs are currently detected incidentally, making the classical triad of flank pain, gross haematuria and palpable abdominal mass less frequent than in the past. Despite this, RCC remains the 'Internist's cancer' with paraneoplastic syndromes such as hypercalcaemia, unexplained fever, erythrocytosis and Stauffer's syndrome (signs of cholestasis unrelated to tumour infiltration of the liver or intrinsic liver disease, which typically resolve after kidney tumour resection), still being relatively frequent.
Suspicion of RCC should prompt laboratory examinations of serum creatinine, haemoglobin, leukocyte and platelet counts, lymphocyte to neutrophil ratio, lactate dehydrogenase, C-reactive protein (CRP) and serum-corrected calcium, in addition to other symptom-derived tests [IV, B] . Some of these tests are prognosticators for survival and are used for risk assessment within different prognostic score systems (see later).
Most cases of RCC are strongly suspected by imaging. Diagnosis is usually suggested by US and further investigated by CT scan, which allows for assessment of local invasiveness, lymph node involvement, or distant metastases. Magnetic resonance imaging (MRI) may provide additional information in investigating local advancement and venous involvement by tumour thrombus.
For accurate staging of RCC, contrast-enhanced chest, abdominal, and pelvic CT is mandatory [III, A]; unless indicated by clinical or laboratory signs or symptoms, the use of bone scan or CT (or MRI) of the brain is not recommended for routine clinical practice [III, A] . In case of an allergy to CT contrast medium, adequate staging should include a high-resolution CT scan of the chest without contrast medium, together with an abdominal MRI. 18 Fluorodeoxyglucose-positron emission tomography ( 18 FDG-PET) is not a standard investigation in the diagnosis and staging of clear cell RCC (ccRCC) and should not be used. The role of new tracers is under investigation only.
A renal tumour core biopsy provides histopathological confirmation of malignancy with high sensitivity and specificity; it is especially recommended before treatment with ablative therapies [III, B] as well as in patients with metastatic disease before starting systemic treatment [III, B] . Nowadays, complications (e.g. bleeding or tumour seeding) are rare or even exceptional (as in the case of tumour seeding) [3] , while diagnostic accuracy remains high [4] . The final histopathological diagnosis, classification, grading and evaluation of prognostic factors are based on the nephrectomy specimen when available.
pathology assessment
The new edition of the World Health Organization (WHO) histological classification of renal tumours has been recently reported (Table 1) and was based on tumour histology, chromosomal alterations and molecular pathways [5] . [7] . First, RCC proved to be an extremely heterogeneous disease [8] ; beyond the seminal genetic alteration (mutation, deletion or hypermethylation) of the VHL tumour suppressor gene, which is present in the vast majority of sporadic RCCs, other genetic alterations may occur, especially over time [9] , contributing to worsen the prognosis of patients harbouring these tumours. Notably enough, three of these other genes (PBRM1, BAP1, and SETD2) are located on the same short arm of chromosome 3 where the VHL gene is also located. Genetic abnormalities to these genes seem to increase tumour aggressiveness [10] , defining these cancers as 'diseases of chromosome 3p'.
On the contrary, some RCCs are characterised by mutations in the mTOR pathway and especially in the highly conserved FAT (FRAP-ATM-TTRAP) and kinase domains of the MTOR gene; these cancers have been defined as metabolic RCCs [11] . When metastatic, they are thought to be more sensitive to mTOR inhibitors [12] .
Finally, according to another comprehensive molecular characterisation of papillary RCCs, type 1 and type 2 papillary RCCs were shown to be clinically and biologically distinct. Alterations in the MET pathway were indeed associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2, while CDKN2A loss, and a CpG island methylator phenotype in type 2 contributed to convey a poor prognosis. Based on this genomic profile, type 2 papillary RCC consisted of at least three subtypes based on molecular and phenotypic features [13] .
Finally, some of the escape mechanisms, namely cMET (cabozantinib) and FGF (fibroblast growth factor, lenvatinib) activation, have been used to develop new strategies in vascular endothelial growth factor (VEGF) refractory patients.
staging and risk assessment staging
The American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumour-node-metastasis (TNM) staging system should be used (Table 2) .
risk assessment
The natural clinical course varies in RCC, which has led to the development of different prognostic models for the assessment of the patient's individual risk. Extent of disease, histology, grading and clinical factors have been recognised as having prognostic value in RCC and may be used in localised or metastatic disease [5] .
localised disease. Different pre-or postoperative scores have been applied to assess prognosis in RCC, which are used for risk-adapted follow-up strategies. Integrated prognostic scores offer some predictive advantages over single tumour characteristics and are used preferentially. These models are composed of histological and clinical factors. The most recent modifications of the stage, size, grade and necrosis (SSIGN) score [14] (Table 3 ) and the University of California Los Angeles Integrated Staging System (UISS) (Table 4) [15] score are frequently used.
However, among different prognostic scores, a concordance of 0.68-0.89 for cancer-specific survival (CSS) and 0.74-0.82 for recurrence-free survival was reported [16] , indicating that a plateau has been reached for prognostication with available models. Hence, no clear preference for a specific prognostic model may be given.
advanced disease. The Memorial Sloane Kettering Cancer Centre (MSKCC) was the gold standard for the risk assessment during cytokine treatment in metastatic (m)RCC [17] . Its applicability to targeted agents was shown more recently [18] . Further refinement was introduced with the International Metastatic RCC Database Consortium (IMDC) score, which extended the previous factors to a total number of 6 to increase concordance [19, 20] :
• Karnofsky performance status (PS) <80%
• Haemoglobin <lower limit of normal • Time from diagnosis to treatment of <1 year • Corrected calcium above the upper limit of normal • Platelets greater than the upper limit of normal • Neutrophils greater than the upper limit of normal A recent evaluation of this model in second-line treatment underscored its predictive value in previously treated mRCC [21] (Table 5 ). molecular prognostication. Gene signatures were known to detect different risk groups in RCC [22] . More recently, a 16-gene assay was shown to improve prediction of recurrence-free survival in localised RCC compared with the SSIGN score according to Leibovich (concordance: 0.81versus 0.74) [23] .
These data indicate that molecular analysis may exert additional benefit to already established clinical and histo-anatomical parameters, which may lead to an individual risk assessment in the future. Other putative markers such as circulating DNA, microRNA or DNA methylation status were shown to have prognostic relevance in RCC and warrant future investigation. As of today, no specific molecular marker can be recommended for clinical use.
management of local/locoregional disease
A summary of the recommendations for treatment of localised and locally advanced disease is shown in Table 6 .
T1 tumours (<7 cm)
• Partial nephrectomy (PN) is recommended as the preferred option in organ-confined tumours measuring up to 7 cm (elective indication). This is based on a systematic review including multiple retrospective studies and a prospective randomised, controlled trial (RCT) which compared radical nephrectomy (RN) with PN in solitary T1a-b N0M0 renal tumours <5 cm with normal contralateral kidney function [I, A] [24] .
• PN can be carried out via open, laparoscopic or laparoscopic robot-assisted approaches.
• Laparoscopic RN is recommended if PN is not technically • Systematic reviews comparing surgical management of localised RCC (T1-2N0M0) were unable to identify prospective comparative studies reporting on oncological outcomes for minimally invasive ablative procedures compared with RN [24] .
• Radio frequency ablation (RFA) or cryoablation (CA) treatments are options in patients with small cortical tumours (≤3 cm), especially for patients who are frail, present a high surgical risk and those with a solitary kidney, compromised renal function, hereditary RCC or multiple bilateral tumours. Renal biopsy is recommended to confirm malignancy and subtype in this setting.
• Systematic reviews of RFA and PN suggest that RFA has a long-term CSS equal to PN with a low metastasis rate but slightly higher local recurrence rate compared with PN and CA [25] . The quality of the available evidence prevents definitive conclusions regarding morbidity and oncological outcomes for RFA and CA [III].
• Active surveillance is an option in elderly patients with significant co-morbidities or those with a short-life expectancy and solid renal tumours measuring <40 mm. The growth of renal tumours (mean 3 mm/year) is low in most cases, and progression to metastatic disease is reported in 1%-2% [26] . Renal biopsy is recommended to select patients with small masses for active surveillance [III] with high accuracy [3, 4] . locally advanced RCC (T3 and T4)
• Open RN remains the standard of care even though a laparoscopic approach can be considered.
• Systematic adrenalectomy or extensive lymph node dissection is not recommended when abdominal CT shows no evidence of adrenal or lymph node invasion [27] .
• The evidence regarding management of venous tumour thrombus is based on retrospective studies with significant risks of bias and confounding. Resection of venous thrombi is challenging and associated with a high risk of complications. Surgical intervention should be considered, but the most effective approach remains unknown and outcome depends on tumour thrombus level [III].
• Currently, there is no evidence from randomised phase III trials that adjuvant therapy is of survival benefit or prolongs disease-free survival (DFS). Several RCTs of adjuvant sunitinib, sorafenib, pazopanib, axitinib and everolimus are ongoing. Data from a large adjuvant trial of sunitinib versus sorafenib versus placebo were reported in 2015 (ASSURE) after an interim analysis carried out with 62% information.
Results demonstrated no significant differences in DFS or overall survival (OS) between the experimental arms and placebo [28] . However, recently a press release announced that the S-TRAC trial, comparing sunitinib to placebo in high-risk localised RCC, met its primary end point. Full data should be presented at the ESMO 2016 meeting. Depending on these data, the role of sunitinib in the adjuvant setting will have to be discussed. Neoadjuvant approaches are experimental and should not be proposed outside clinical trials.
• Attempting to downsize venous tumour thrombi with systemic targeted therapy cannot be recommended. 
systemic treatment
An algorithm for systemic treatment in mRCC is presented in Figure 1 .
Recommendations mainly relate to clear cell histology, since most of the pivotal trials have been done in this common histological subtype. In addition, recommendations will differ according to risk stratification (see above).
The time to start systemic therapy is not well defined. Because some RCCs have a very indolent course, a period of observation before starting treatment should be considered, especially in patients with limited tumour burden and few symptoms. Indeed, the outcome of patients who crossed over to an active agent after a brief period of treatment with placebo, within placebo-controlled phase III trials, indirectly supports this option [II, C]. The safety of observation has also been suggested by retrospective and prospective studies.
first-line treatment of patients with good or intermediate prognosis.
• Three treatments have demonstrated efficacy in pivotal phase III trials: bevacizumab (combined with interferon), sunitinib and pazopanib [30] [31] [32] . All three drugs have been registered based on improvement of progression-free survival (PFS) over either interferon or placebo. More recently, pazopanib has been shown not to be inferior to sunitinib in a large phase III trial [33] . Efficacy of both sunitinib and pazopanib has been confirmed by real-world evidence studies. These two tyrosine kinase inhibitors (TKIs) are currently the most commonly used treatments. Considering all of the published trials, the level of recommendation is considered to be [I, A] for all three regimens.
• • Single-agent interferon-alpha, as the inferior arm of three RCTs, should no longer be regarded as a standard option [I, D] . There is currently no evidence that new checkpoint inhibitors should be used in first line, although numerous ongoing trials are exploring their role, either as monotherapy or in combination (with either VEGF inhibitors or other checkpoint inhibitors).
• Interestingly, very recently, cabozantinib has been reported to be superior to sunitinib in a randomised phase 2 trial. If these results are confirmed, the role of cabozantinib in the first-line setting will have to be assessed. first-line treatment of patients with poor prognosis.
• Temsirolimus is currently the only drug tested in a phase III study, demonstrating evidence of activity in this patient population [II, A] [34] . The pivotal trial demonstrated improvement of OS compared with interferon or the combination of temsirolimus and interferon.
• Based on subgroup analysis from the pivotal trial, as well as expanded access programmes, sunitinib is another reasonable • There is no clear recommendation on whether temsirolimus or TKIs should be used in poor risk patients, although TKIs are more commonly used in patients with good PS (expert opinion). The advantage of using TKIs in this setting will be to use second-line recommendations below, as some patients in the second-line trials were in the poor prognostic group.
• It is clear that, for some poor prognosis patients, best supportive care remains the only suitable treatment option.
second-line treatment.
• [32, 35, 36] . Sunitinib also has activity is this setting [III, A]. However, since VEGF-targeted therapy is now the first-line standard of care, the number of patients treated with cytokines is decreasing.
• After first-line treatment with VEGF-targeted therapy, ○ Both axitinib [II, B] and everolimus [II, B] are active [36, 37] . Both drugs have shown significantly improved PFS over sorafenib (axitinib) or placebo (everolimus).
○ Based on recent phase III trials, sorafenib can also be used as an option [III, B].
• However, second-line treatment has recently been dramatically modified by the report of two large trials showing improvement in OS with nivolumab [an anti-programmed death 1 (PD-1) inhibitor] and cabozantinib [38] [39] [40] over everolimus. Both trials showed very significant improvement in OS and response rate, while PFS was improved only in the cabozantinib trial. In both trials, patients could be treated after either one or two TKIs.
• Obviously, availability of these two drugs is still very limited, and several situations should be differentiated: • Of note, the combination of lenvatinib and everolimus has recently been approved by the FDA (Food and Drug Administration) based on a randomised study of 150 patients, showing PFS and OS benefit over everolimus [41] . Recently in Europe, the CHMP (Committee for Medicinal Products for Human Use) gave a positive opinion for this combination. However, based on the size of this study, this combination cannot, at this stage, be added to current European guidelines.
• Finally, the optimal duration of treatment, especially for nivolumab, remains questionable, as well as the benefit of treatment beyond progression.
third-line treatment. Beyond second-line treatment, enrolment into clinical trials is recommended where possible. However, based on recent trials with nivolumab and cabozantinib, different situations should be defined:
• medical treatment of metastatic disease of non-clear cell histology. For these patients, enrolment into specifically designed clinical trials is strongly recommended. However, small prospective trials as well as subgroup analyses from larger trials have recently been reported [43] [44] [45] . In these trials, sunitinib and everolimus have been compared, and in every trial, there is a trend in favour of sunitinib. In addition, some recommendations can be provided according to the results of the expanded access programmes of sunitinib and sorafenib, of small retrospective studies, and of the subgroup analysis of the temsirolimus registration trial. Overall, sunitinib has the most reproducible efficacy [II, B] . These studies also suggest that patients with non-clear cell histology may benefit from treatment with everolimus [III, B], sorafenib, pazopanib or temsirolimus [III, B] . However, in most of these studies, only patients with papillary and chromophobe tumours were enrolled.
In the absence of prospective data, genetic considerations may influence treatment decisions: in papillary type 1 tumours, activation of the c-MET pathway has commonly been reported. Novel agents inhibiting the cMET receptor are currently under investigation. However, as the c-MET receptor and VEGF-receptor were shown to cooperate, VEGF-inhibiting agents may be a reasonable choice. Similarly, there is no evidence for the optimal treatment of papillary type 2, which is characterised by inactivation of the fumarate-hydratase gene, fumarate accumulation and HIF upregulation. Again, VEGF inhibitors may be considered in this context. Patients with chromophobe RCC may benefit from mTOR inhibitors since mutation on chromosome 7 was shown to lead to a loss of the folliculin gene with up-regulation of mTOR. Finally, collecting duct tumours (and also medullary carcinomas) were reported to behave more like aggressive urothelial tumours rather than RCCs and may therefore be considered for chemotherapy. None of these 'genetic' recommendations can be graded, as data are limited and no clear treatment recommendation can be made for these subgroups with distinct biology.
role of radiotherapy and bisphosphonates
The spectrum of radiosensitivity in RCC is wide, but it is not a radioresistant disease. Radiotherapy has been shown to provide good symptom palliation and local control in RCC depending on the dose that can be delivered [46] . There is a developing rationale with emerging data suggesting that the apparent radioresistance of RCC can be overcome through the ceramide pathway with the use of higher dose per fraction treatments usually delivered by new high-precision radiotherapy methods such as SBRT [IV, B] [47] . This can be exploited and used in many different clinical situations particularly for unresectable local recurrences or oligometastatic disease.
• There is no current evidence for the use of radiotherapy in the neoadjuvant or adjuvant setting. This is on the basis of four negative 'old' trials with two pre-operative and two adjuvant studies. Despite being randomised trials, there are several major limitations in trial design and methodology that included inappropriate case selection, sub-therapeutic radiotherapy regimes and inadequate patient numbers. Furthermore, treatment morbidity was substantially high and the radiotherapy techniques used then have now been superseded by improved modern irradiation methods such as intensity-modulated radiotherapy or SBRT [II, D].
• Radiotherapy can be used to treat unresectable local or recurrent disease with the aim of improving local control. For patients in whom surgery cannot be carried out due to poor PS or unsuitable clinical condition, radiotherapy can be an alternative if other local therapies such as radioablation are not appropriate. Modern image-guided radiotherapy techniques are needed to enable a high biological dose to be delivered, such as volumetric modulated arc therapy (VMAT) or SBRT [IV, B]. As discussed earlier, there is an emerging role for its use in the synchronous or metachronous development of oligometastatic mRCC disease, oligoprogression or in mixed response scenarios with immuno-or targeted therapies [IV, B].
• Radiotherapy is an effective treatment for palliation of local • For the management of spinal cord compression, an ambulatory status at diagnosis and limited metastatic disease are favourable prognostic factors in those patients able to undergo surgery. The use of initial surgery and postoperative radiotherapy was reported in a randomised trial to improve survival and maintenance of ambulation compared with irradiation alone [48] [49] [50] Multidisciplinary management is needed to optimise care for mRCC patients suffering from bone metastasis. The approach will need to be individualised to the extent of bone metastasis, its location and potential consequences (see sections above on radiotherapy palliation and spinal cord compression). In widespread mRCC bone metastasis, bisphosphonate therapy with zoledronic acid has been shown to significantly reduce skeletalrelated events (SREs) in patients and increase time to first SRE [51] . Denosumab is a synthetic RANK ligand inhibitor that may have a greater bone effect as it is capable of reaching all sites within bone (being a circulating antibody), compared with bisphosphonates, which have a greater affinity for sites of active bone turnover. Denosumab has been shown in a randomised trial to extend the time to first SRE by 4.3 months and was noninferior to zoledronic acid [52] . In addition, denosumab has the convenience of subcutaneous administration with no requirement for renal monitoring or dose adjustment [I, A]. Bonetargeted therapy with either zoledronic acid or denosumab should be considered in mRCC patients with reasonable life expectancy and widespread bony metastasis weighting the potential benefits of the treatment (supposed benefit in terms of OS) Levels of evidence I Evidence from at least one large randomised, controlled trial of good methodological quality (low potential for bias) or meta-analyses of wellconducted randomised trials without heterogeneity II Small randomised trials or large randomised trials with a suspicion of bias (lower methodological quality) or meta-analyses of such trials or of trials with demonstrated heterogeneity III Prospective cohort studies IV Retrospective cohort studies or case-control studies V Studies without control group, case reports, experts opinions Grades of recommendation A Strong evidence for efficacy with a substantial clinical benefit, strongly recommended B Strong or moderate evidence for efficacy but with a limited clinical benefit, generally recommended C Insufficient evidence for efficacy or benefit does not outweigh the risk or the disadvantages (adverse events, costs, etc.), optional D Moderate evidence against efficacy or for adverse outcome, generally not recommended E Strong evidence against efficacy or for adverse outcome, never recommended a By permission of the Infectious Diseases Society of America [54] .
